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Abstract
Background: Laboratory evidence suggests that vitamin D might influence prostate cancer prognosis.
Methodology/Principal Findings: We examined the associations between prediagnostic plasma levels of 25(OH)vitamin D
[25(OH)D] and 1,25(OH)2vitamin D [1,25(OH)2D] and mortality among 1822 participants of the Health Professionals Follow-
up Study and Physicians’ Health Study who were diagnosed with prostate cancer. Cox proportional hazards models were
used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of total mortality (n=595) and lethal prostate cancer
(death from prostate cancer or development of bone metastases; n=202). In models adjusted for age at diagnosis, BMI,
physical activity, and smoking, we observed a HR of 1.22 (95% CI: 0.97, 1.54) for total mortality, comparing men in the lowest
to the highest quartile of 25(OH)D. There was no association between 1,25(OH)2D and total mortality. Men with the lowest
25(OH)D quartile were more likely to die of their cancer (HR: 1.59; 95% CI: 1.06, 2.39) compared to those in the highest
quartile (Ptrend=0.006). This association was largely explained by the association between low 25(OH)D levels and advanced
cancer stage and higher Gleason score, suggesting that these variables may mediate the influence of 25(OH)D on prognosis.
The association also tended to be stronger among patients with samples collected within five years of cancer diagnosis.
1,25(OH)2D levels were not associated with lethal prostate cancer.
Conclusions/Significance: Although potential bias of less advanced disease due to more screening activity among men
with high 25(OH)D levels cannot be ruled out, higher prediagnostic plasma 25(OH)D might be associated with improved
prostate cancer prognosis.
Citation: Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, et al. (2011) Prediagnostic Plasma Vitamin D Metabolites and Mortality among Patients with
Prostate Cancer. PLoS ONE 6(4): e18625. doi:10.1371/journal.pone.0018625
Editor: Zheng Su, Genentech Inc., United States of America
Received January 26, 2011; Accepted March 8, 2011; Published April 6, 2011
Copyright:  2011 Fang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health research grants CA133891, CA141298, CA34933, CA40360, CA091793, CA055075,
CA42182, HL26490 and HL34595; Prostate Cancer Foundation, Santa Monica, CA, USA and National Cancer Institute National Research Service Award T32
CA09001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: fang.fang@channing.harvard.edu
Introduction
The first proposal of the hypothesis that vitamin D protects
against prostate cancer appeared already two decades ago [1],
followed by experimental studies suggesting that vitamin D may
play an important role in the natural history of prostate cancer,
not only for occurrence but also for disease progression through
invasion, angiogenesis, and metastases [2–4]. Most epidemiolog-
ical studies examining the associations between circulating levels
of prediagnostic vitamin D metabolites (25(OH)vitamin D
[25(OH)D] and 1,25(OH)2vitamin D [1,25(OH)2D]) and prostate
cancer risk have reported null results [5–12]. Human studies have
focused more recently on possible influences of vitamin D in
prostate cancer progression, including a Norwegian study showing
that a higher level of serum 25(OH)D after diagnosis was
associated with a better prognosis of prostate cancer [13].
However, in that study blood samples were collected after prostate
cancer diagnosis, and thus the 25(OH)D levels might already have
been influenced by the cancer, by treatment, or by alterations in
outdoor activities or diet after the cancer diagnosis. Further
support for a possible influence of vitamin D on prognosis comes
from studies showing that genetic variants in the vitamin D
receptor are associated with Gleason score [14], and genetic
variants in the vitamin D pathway are associated with risk of
recurrence or progression and prostate cancer-specific mortality
[15]. In the present study, we examined the hypothesis that higher
plasma levels of prediagnostic vitamin D metabolites, 25(OH)D
and 1,25(OH)2D, are associated with better prognosis of prostate
cancer in two prospective cohort studies: the Health Professionals
Follow-up Study and the Physicians’ Health Study.
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Ethics Statement
The Human Subjects Committee at the Harvard School of
Public Health and the Human Subjects Committee at Brigham
and Women’s Hospital approved this study. Written consent was
given by the patients for their information to be stored in the
hospital database and used for research.
Study populations
Health Professionals Follow-up Study (HPFS). The HPFS
is an ongoing prospective cohort study of 51,529 US men who
were aged 40–75 years at enrollment in 1986, and followed
through biennial questionnaires [16]. The participants reported
information on height (at baseline only), body weight, physical
activity and diet every two or four years. In 1993–1995, 18,018
men in the cohort donated a blood sample. Participants with a
diagnosis of any cancer except non-melanoma skin cancer prior to
the blood draw were excluded from the present analysis.
For each man who reported a prostate cancer diagnosis on a
follow-up questionnaire or for whom a death certificate indicated
that the cause of death was prostate cancer, we obtained medical
and pathology records after receiving written permission from the
participants or their next-of-kin. The response rate was 96% for
nonfatal cases and we estimate having ascertained .98% of fatal
cases [17]. Medical records and pathology reports were success-
fully obtained for 90% of the cases in the cohort. A study
investigator blinded to questionnaire and assay information
reviewed the medical records to confirm adenocarcinoma of the
prostate and to abstract information on stage (according to the
TNM staging scheme) and Gleason sum of the tumor. Patients
without pathologic staging were classified as indeterminate stage
unless there was clinical evidence of distant metastases at
diagnosis.
Physicians’ Health Study (PHS). The PHS I was a
randomized, double-blind, placebo-controlled trials of aspirin
and b-carotene among 22,071 healthy US male physicians, aged
40–84 years, that began in 1982 [18]. Study participants provided
baseline information via self-administrated questionnaires. Before
randomization, 14,916 men (68%) provided a blood sample [7],
and more than 70% of the specimens were received during
September-November in 1982. Additional questionnaires were
mailed at 6 months, 12 months, and annually thereafter to obtain
medical information, including data on height, body weight and
physical activity. Study investigators, blinded to the questionnaire
or assay data, verified the reports of prostate cancer by participants
and reviewed medical records and pathology reports to determine
the tumor Gleason score and stage (according to the TNM
classification scheme). If pathologic staging was not available, cases
were classified as indeterminate stage unless there was clinical
evidence of distant metastases at the time of diagnosis.
Laboratory measurements
Vitamin D Metabolites. Plasma concentrations of
1,25(OH)2D and 25(OH)D were determined by radioimmunosor-
bant assay in the laboratory of Dr. Bruce Hollis [19,20]. In the
HPFS, cases were assayed in four separate analytical runs (cases up
to January 1996, February 1996-January 1998, February 1998-
January 2000, and February 2000–January 2004) [21,22]. The
PHS cases were assayed in two analytic runs [23,24]. The mean
intrapair coefficients of variation from blinded quality control
samples ranged from 5–10% for both 25(OH)D and 1,25(OH)2D
in PHS and HPFS [21–24].
To assess the intraperson consistency of vitamin D metabolite
concentrations over time, we measured 1,25(OH)2D and
25(OH)D for 144 men in the HPFS who were free of cancer
diagnosis and who provided a blood sample in 1993/1994 and
again in 1997 (mean of 3.0360.46 years apart) [21]. Adjusting for
age, race, and season of the year, the Pearson correlation
coefficients between the two time points were 0.50 (P,0.0001)
for 1,25(OH)2D and 0.70 (P,0.0001) for 25(OH)D.
Follow-up of participants with prostate cancer
From the two cohorts, we identified a total of 1822 men
diagnosed with prostate cancer after blood collection on whom
circulating levels of vitamin D had been previously measured as
part of nested case-control studies of vitamin D metabolites and
risk of incident prostate cancer; 1318 in HPFS (diagnosed during
1993–2004) and 504 in PHS (diagnosed during 1982–1998) [21–
24]. A total of 185 patients (10.2%) were diagnosed within 2 years
after blood collection. All cancer patients were followed from the
date of cancer diagnosis until date of death, bone metastasis, or
end of the current follow-up (July 17, 2009 in HPFS and March
31, 2009 in PHS), whichever came first. Information on the course
of prostate cancer was collected through follow-up questionnaires,
which collected treatments and development of metastases. When
a metastasis was reported, we contacted the treating physician of
the patient and requested a review of the relevant medical records
to verify the diagnosis. Consent was obtained from the participants
to review the medical records. Information on date and cause of
death was obtained from repeated mailings and searches on the
National Death Index and confirmed through review of death
certificates and medical records. Deaths due to prostate cancer
were based on evidence of metastases and disease progression,
with no other plausible cause of death. A bone metastasis or death
from prostate cancer was taken as the end point when calculating
hazard ratios for prostate cancer-specific mortality; death from any
cause was used as the endpoint when calculating hazard ratios for
total mortality.
Statistical analysis
Because vitamin D metabolites were assayed in different batches
from blood samples collected at various seasons, and the vitamin D
metabolites levels (especially 25(OH)D) vary largely with season,
we calculated the batch-, season-, and cohort-specific quartiles for
1,25(OH)2D and 25(OH)D. Seasons were classified as follows:
summer (June-August), autumn (September–November), spring
(March–May), and winter (December–February). In HPFS, the
mean (standard deviation) values of the quartiles standardized for
batch and season as described by Rosner et al. [25] are 20.36
(6.83), 30.24 (3.72), 37.26 (4.88) and 49.03 (10.04) pg/ml for
1,25(OH)2D; and 16.19 (4.46), 23.51 (2.24), 28.78 (3.16), and
38.35 (7.18) ng/ml for 25(OH)D. Similarly, in PHS, 24.10 (3.23),
29.84 (1.40), 34.66 (1.60), and 44.47 (6.59) pg/ml for 1,25(OH)2D;
and 17.55 (3.98), 25.42 (2.38), 31.12 (2.39), and 42.78 (7.84) ng/ml
for 25(OH)D. We used ANOVA tests to examine the differences in
the means of age at blood draw, age at cancer diagnosis, and
follow-up time across the quartiles of vitamin D metabolites. A
two-way chi-square test was used to obtain P values for the
associations of Gleason score, TNM stage, smoking status, body
mass index (BMI), and physical activity with the quartiles of
vitamin D metabolites.
Cox proportional hazards regression models were used to
estimate hazard ratios (HRs) and their 95% confidence intervals
(CIs) to assess the relation of plasma vitamin D metabolites with
total and prostate cancer-specific mortality. The highest quartile
was used as the reference group for both 1,25(OH)2D and
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and 1,25(OH)2D treating the quartiles (1,2,3,4) as a continuous
variable. We hypothesized that tumor grade and stage might be
the intermediate factors relating vitamin D to prostate cancer
progression; therefore we adjusted first for age at diagnosis,
smoking (never vs. ever), BMI (,25, $25 and ,28, or $28 kg/
m
2), and physical activity (low, moderate, or high) obtained from
the questionnaire collected before the blood donation. In
additional models, we further adjusted for Gleason score (,7, 7,
.7, or missing) and TNM stage (T1/T2, T3, T4/N1/M1, or
missing) to assess the potential of vitamin D metabolites in
predicting cancer prognosis beyond these tumor characteristics.
The proportional hazard assumption was checked and found to
hold for all covariates. Analyses were first conducted among these
two cohorts separately. Because the findings were similar, we
combined these two cohorts to increase statistical power and we
report only results obtained from the pooled analyses.
We further stratified the analyses by age at diagnosis (,65 or
$65 years), tumor stage (TNM: T1/T2 or T3/T4/N1/M1), and
Gleason score (,7o r$7). To alleviate concern of reverse
causality (i.e., prostate cancer influencing the levels of vitamin D
metabolites), in a sub-analysis, we excluded patients with samples
collected ,2 years before prostate cancer diagnosis. We also
conducted stratified analyses by the time interval between blood
draw and prostate cancer diagnosis (,5o r$5 years). All P values
are two-sided and considered statistically significant at P , 0.05.
All analyses were performed using SAS, version 9.1 (SAS Institute,
Cary, NC, USA).
Results
The mean age (standard deviation, SD) at blood draw of
participants in the analysis was 63.7 (7.8) years in HPFS and 59.2
(7.6) years in PHS. The mean age (SD) at cancer diagnosis was
69.5 (7.4) years in HPFS and 67.8 (6.5) years in PHS.
Characteristics of the prostate cancer patients in the combined
analyses are presented in Table 1.
Higher 25(OH)D levels were associated with lower BMI
(P,0.0001), more physical activity (P,0.0001), and also lower
Gleason score at prostate cancer diagnosis (P=0.02) (Table 1).
Although not statistically significant, higher 25(OH)D levels were
associated with a lower frequency of metastatic prostate cancer.
Higher 1,25(OH)2D level was associated with younger age
(P=0.0007) as well as lower BMI (P=0.02). During follow-up,
we documented 595 deaths including 166 cases of death from
prostate cancer, and 36 men living with bone metastasis; we
combined the prostate cancer deaths and metastatic cases into a
single category of lethal prostate cancer (n=202).
Among the men with prostate cancer, those with the lowest
levels of 25(OH)D based on quartiles had a slightly increased total
mortality compared to patients with the highest quartile. After
adjustment for age at diagnosis, BMI, physical activity, and
smoking, the HR was 1.22 (95% CI: 0.97, 1.54); a test for linear
trend was suggestive, but not statistically significant (Ptrend=0.07)
(Table 2).
Men in the lowest quartile of 25(OH)D had a higher risk of
lethal prostate cancer, after adjustment for age at diagnosis, BMI,
physical activity, and smoking (HR: 1.59; 95% CI: 1.06, 2.39); a
statistically significant dose-response relationship was also ob-
served (P=0.006) (Table 2). This association was largely
explained by the association between 25(OH)D levels and
advanced stage and higher Gleason score; after adjustment for
those factors, the association was diminished and no longer
significant (Table 2). No association was observed for
1,25(OH)2D with either total mortality or lethal prostate cancer
(Table 2). In separate analyses by cohort, after adjustment for age
at diagnosis, physical activity, and smoking, the lowest quartile of
25(OH)D was statistically significantly associated with a higher risk
of lethal prostate cancer in HPFS (HR: 2.01; 95% CI: 1.12, 3.59),
but the association was not as apparent in PHS (HR: 1.17; 95%
CI: 0.66, 2.09).
In analyses excluding patients with prostate cancer diagnosed
within 2 years after blood draw, we observed a diminished
association between 25(OH)D and lethal prostate cancer, after
adjustment for age at diagnosis, BMI, physical activity, and
smoking (HR: 1.42; 95% CI: 0.91, 2.22). Stratified analyses by the
time interval between blood draw and prostate cancer diagnosis
showed an association between 25(OH)D and lethal prostate
cancer only among men with blood sample collected ,5 years
before cancer diagnosis (HR: 1.90; 95% CI: 1.07, 3.38), but not
among those with blood sample collected $5 years before cancer
diagnosis (HR: 1.22; 95% CI: 0.66, 2.27).We found no material
differences in the associations stratified by age, stage at diagnosis,
or Gleason score (data not shown).
Discussion
Using prospectively collected plasma samples, we found that
prostate cancer patients with a lower concentration of prediag-
nostic plasma 25(OH)D had a higher risk of developing metastatic
or fatal (lethal) prostate cancer. Circulating 1,25(OH)2D level was
not associated with either total mortality or lethal prostate cancer.
The association between 25(OH)D and prostate cancer-specific
mortality appeared to be mediated mainly through Gleason score
and TNM stage at diagnosis; after adjustment for these tumor
characteristics, the associations were no longer statistically
significant. Such mediation is biologically plausible since vitamin
D promotes differentiation and apoptosis while inhibiting
angiogenesis and proliferation [2–4,26], processes that can affect
tumor grade and stage. Accordingly, statistical adjustment for
Gleason score and TNM stage would tend to lead to null results.
Our results suggest that 25(OH)D level may be biologically and
clinically relevant, but this level may not add prognostic value in
addition to tumor stage and grade. The different results between
25(OH)D and 1,25(OH)2D might be due to the fact that levels of
1,25(OH)2D are known to be tightly regulated and circulating
1,25(OH)2D does not reflect nutritional status of vitamin D except
at severe deficiency states and hence probably does not assess of
intracellular 1,25(OH)2D in the prostate.
The inverse association between 25(OH)D level and lethal
prostate cancer was only seen among men with blood samples
collected less than five years before cancer diagnosis. This finding
may reflect that 25(OH)D level at late stages of tumor development
modifies prostate cancerprognosis. This strongerassociation among
men with more recent blood draw could potentially explain the
stronger association observed in the HPFS compared to the PHS,
since there was on average a shorter time interval between blood
draw and prostate cancer diagnosis, i.e., more of the prostate
cancers in HPFS were diagnosed within five years after the blood
draw. On the other hand, this finding might also reflect a possibility
of reverse causality, i.e., a preclinical occult cancer might reduce
25(OH)D levels. However, most cases were diagnosed at an early
stage, and results persisted when the analyses were limited to
cancers diagnosed at early stage (among patients with either
Gleason score ,7 or TNM stage in T1/T2, a HR of 1.64 [95% CI:
0.90, 2.98] was observed). If reverse causality entirely explained our
findings we might have expected that prediagnostic 25(OH)D was
more strongly predictiveofoutcome foradvanced stage diseasethan
Vitamin D and Prostate Cancer Prognosis
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although somewhat attenuated, associations were still observed after
excluding those who had blood samples collected within two years
of diagnosis. We believe that our medical records review for
metastasis cases was rather comprehensive, while it is still possible
that we misclassified or missed some metastases (e.g., men died
before questionnaire was sent). Such misclassification or missingness
should however be largely non-differential with respect to
prediagnostic vitamin D levels and theoretically only lead to an
underestimation of the real association.
We considered whether the association between 25(OH)D and
lethal prostate cancer may have been explained by confounding or
bias. Although confounding cannot be ruled out, we controlled for
BMI and physical activity, which influence vitamin D levels and
may affect prostate cancer prognosis. Also possible is that
participants with higher 25(OH)D levels may have more frequent
prostate cancer screening compared to those with lower levels,
leading to the detection of more indolent, earlier staged tumors.
Participants with higher 25(OH)D levels are presumably more
health conscious compared with participants with lower levels, this
is evidenced in our data as high 25(OH)D level was associated with
more outdoor physical activities. Health consciousness is related to
the participation in prostate cancer screening; for example,
according to a national survey, physician counsel and patient
prevention consciousness are the major influences when a patient
decides to attend prostate carcinoma testing in the United States
[27]. However, the rate of PSA screening tends to be uniformly
high in these cohorts of physicians and health professionals. For
example, approximately 80% of the prostate cancer patients in the
HPFS had at least one PSA screening test before blood donation
[7]. In addition, participation in PSA screening did not seem to be
associated with 25(OH)D levels in our data. For instance, PSA
Table 1. Baseline Characteristics of 1822 men with prostate cancer according to Quartiles of Plasma 25(OH)D and 1,25(OH)2D,
HPFS (1993) and PHS (1982).
25(OH)D 1,25(OH)2D
Q1 (low) Q2 Q3 Q4 (high) p value Q1 (low) Q2 Q3 Q4 (high) p value
No. of cases 468 458 450 446 470 449 458 445
Age at blood
draw, yrs
62.8 (8.1) 62.2 (8.1) 62.6 (7.6) 62.2 (8.2) 0.42
1 63.5 (8.2) 62.6 (7.7) 61.8 (7.9) 61.9 (8.1) 0.0007
1
Age at diagnosis,
yrs
69.2 (7.2) 68.8 (7.3) 69.2 (7.1) 68.9 (7.3) 0.77
1 70.0 (7.3) 69.3 (6.9) 68.4 (7.3) 68.3 (7.4) ,0.0001
1
Mean follow-up,
yrs
9.7 (4.3) 9.9 (4.4) 10.2 (4.1) 10.0 (4.5) 0.13
1 9.7 (4.2) 10.0 (4.4) 10.0 (4.3) 10.0 (4.5) 0.33
1
Gleason score
Gleason ,7 222 (47.4) 200 (43.7) 252 (56.0) 233 (52.2) 237 (50.4) 215 (47.9) 221 (48.3) 234 (52.6)
Gleason =7 136 (29.1) 155 (33.8) 130 (28.9) 129 (28.9) 148 (31.5) 135 (30.1) 142 (31.0) 125 (28.1)
Gleason .7 61 (13.0) 50 (10.9) 36 (8.0) 47 (10.5) 0.02
2 48 (10.2) 50 (11.1) 50 (10.9) 46 (10.3) 0.89
2
Missing 49 (10.5) 53 (11.6) 32 (7.1) 37 (8.3) 37 (7.9) 49 (10.9) 45 (9.8) 40 (9.0)
TNM stage
T1/T2 335 (71.6) 326 (71.2) 348 (77.3) 346 (77.6) 332 (70.6) 338 (75.3) 346 (75.6) 339 (76.2)
T3 57 (12.2) 61 (13.3) 53 (11.8) 46 (10.3) 67 (14.3) 51 (11.4) 51 (11.1) 48 (10.8)
T4/N1/M1 26 (5.6) 22 (4.8) 14 (3.1) 16 (3.6) 0.26
2 23 (4.9) 14 (3.1) 23 (5.0) 18 (4.0) 0.36
2
Missing 50 (10.7) 49 (10.7) 35 (7.8) 38 (8.5) 48 (10.2) 46 (10.2) 38 (8.3) 40 (9.0)
Smoking status
Never 225 (48.1) 245 (53.5) 208 (46.2) 215 (48.2) 239 (50.8) 215 (47.9) 229 (50.0) 210 (47.2)
Ever 243 (51.9) 213 (46.5) 242 (53.8) 231 (51.8) 0.15
2 231 (49.2) 234 (52.1) 229 (50.0) 235 (52.8) 0.65
2
Body mass index (kg/m
2)
,25 200 (42.7) 216 (47.2) 211 (46.9) 244 (54.7) 205 (43.6) 208 (46.3) 223 (48.7) 235 (52.8)
$25 and ,28 152 (32.5) 154 (33.6) 163 (36.2) 152 (34.1) 159 (33.8) 154 (34.3) 163 (35.6) 145 (32.6)
$28 116 (24.8) 88 (19.2) 76 (16.9) 50 (11.2) ,0.0001
2 106 (22.6) 87 (19.4) 72 (15.7) 65 (14.6) 0.02
2
Physical activity
Low 212 (45.3) 161 (35.2) 159 (35.3) 132 (29.6) 188 (40.0) 151 (33.6) 162 (35.4) 163 (36.6)
Moderate 151 (32.3) 157 (34.3) 151 (33.6) 143 (32.1) 158 (33.6) 151 (33.6) 162 (35.4) 131 (29.4)
High 104 (22.2) 139 (30.4) 138 (30.7) 169 (37.9) ,0.0001
2 122 (26.0) 146 (32.5) 132 (28.8) 150 (33.7) 0.09
2
Missing 1 (0.2) 1 (0.2) 2 (0.4) 2 (0.4) 2 (0.4) 1 (0.2) 2 (0.4) 1 (0.2)
No. of deaths 171 147 143 134 0.19
2 168 143 139 145 0.35
2
No. of lethal
cases
64 57 41 40 0.05
2 55 47 52 48 0.93
2
1ANOVA test.
2Chi-square test. Individuals with missing values were excluded from test.
doi:10.1371/journal.pone.0018625.t001
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square test; P=0.41).
Although we had only one measurement for the vitamin D
metabolites, the good correlation between two measures of both
metabolites taken three years apart among 144 men suggests that
one measurement of the circulating levels is reasonably represen-
tative. Another limitation of the present study is that the plasma
samples were collected in different seasons, and samples from the
two cohorts were measured at six separate times, years apart,
albeit in the same laboratory. We used the season-, batch-, and
cohort-specific cutoffs to define the quartiles of vitamin D
metabolites, preventing the possibility of comparing absolute
levels of the metabolites with other studies. Despite the batch and
seasonal variations in absolute levels of 25(OH)D, each of the
within-batch coefficients of variation ranged from 5 to 10%, and
thus ranking by 25(OH)D status was acceptable.
Other data on vitamin D and prostate cancer prognosis are
sparse. A previous study from Norway observed a strong
association between low level of serum 25(OH)D and a higher
risk of death from prostate cancer [13]. Using serum samples
collected either at the time of or after cancer diagnosis could
potentially be problematic. As the authors discussed, the disease
status might have influenced 25(OH)D concentration due to
reduced outdoor physical activity and less vitamin D supplemen-
tation [13]. The stronger association between 25(OH)D and better
survival for prostate cancer among patients who had hormonal
treatment before sample collection also supports this suspicion. In
addition, treatment for prostate cancer could alter the vitamin D
level as well as influencing cancer prognosis. Our study used
samples collected before diagnosis, and thus avoids these
limitations. Other support of the vitamin D pathway on prostate
cancer prognosis is that genetic variants in the vitamin D receptor
are associated with Gleason score [14], genetic variants in the
vitamin D pathway are associated with risk of recurrence/
progression and prostate cancer-specific mortality [15], and the
high expression of the vitamin D receptor in prostatectomy
Table 2. Hazards ratios (HRs) and 95% confidence intervals (CIs) for total mortality and lethal prostate cancer among prostate
cancer patients by quartiles of vitamin D metabolites, combining HPFS and PHS (N=1822).
Total mortality
No.
Rate per 1000
person-years
1 HR1
2 (95% CI) HR2
2 (95% CI) HR3
2 (95% CI)
25(OH)D
Q1 (low) 171 37.9 1.22 (0.97–1.54) 1.16 (0.92–1.47) 1.10 (0.87–1.39)
Q2 147 32.4 1.09 (0.86–1.38) 1.06 (0.83–1.34) 1.05 (0.83–1.34)
Q3 143 31.2 1.01 (0.79–1.28) 1.06 (0.84–1.35) 1.06 (0.83–1.34)
Q4 (high) 134 30.0 1.00 1.00 1.00
Ptrend 0.07 0.23 0.46
1,25(OH)2D
Q1 (low) 168 36.7 0.97 (0.77–1.22) 0.96 (0.77–1.21) 0.92 (0.73–1.16)
Q2 143 32.0 0.89 (0.70–1.13) 0.88 (0.69–1.11) 0.88 (0.69–1.11)
Q3 139 30.3 0.94 (0.74–1.18) 0.92 (0.73–1.16) 0.93 (0.73–1.17)
Q4 (high) 145 32.5 1.00 1.00 1.00
Ptrend 0.72 0.70 0.43
Lethal Prostate cancer
No.
Rate per 1000
person-years
1 HR1
2 (95% CI) HR2
2 (95% CI) HR3
2 (95% CI)
25(OH)D
Q1 (low) 64 14.2 1.59 (1.06-2.39) 1.46 (0.97–2.20) 1.31 (0.86–1.99)
Q2 57 12.6 1.43 (0.95–2.16) 1.31 (0.87–1.98) 1.32 (0.87–2.00)
Q3 41 9.0 0.98 (0.63–1.52) 1.14 (0.74–1.78) 1.09 (0.70–1.70)
Q4 (high) 40 9.0 1.00 1.00 1.00
Ptrend 0.006 0.06 0.14
1,25(OH)2D
Q1 (low) 55 12.0 0.95 (0.64–1.41) 0.95 (0.63–1.41) 0.85 (0.57–1.27)
Q2 47 10.5 0.87 (0.58–1.31) 0.84 (0.56–1.26) 0.89 (0.59–1.34)
Q3 52 11.3 1.01 (0.68–1.49) 0.95 (0.64–1.41) 0.97 (0.65–1.45)
Q4 (high) 48 10.8 1.00 1.00 1.00
Ptrend 0.66 0.68 0.38
1Crude mortality rate.
2HR1: adjusted for age at diagnosis, body mass index, physical activity, and smoking; HR2: adjusted for age at diagnosis, body mass index, physical activity, smoking, and
Gleason score; HR3: adjusted for age at diagnosis, body mass index, physical activity, smoking, Gleason score, and TNM stage; 25(OH)D and 1,25(OH)2D were mutually
adjusted.
doi:10.1371/journal.pone.0018625.t002
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all studies also have reported better prognosis of prostate cancer
for cases diagnosed and presumably treated in the summer/
autumn months, when 25(OH)D levels tend to be higher [29–31].
In summary, we observed an inverse association of 25(OH)D
with risk of lethal prostate cancer. These data further support the
potential influence of the vitamin D pathway on prostate cancer
prognosis.
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